Literature DB >> 8484262

Inhibition of beta-glucuronidase by natural glucuronides of kampo medicines using glucuronide of SN-38 (7-ethyl-10-hydroxycamptothecin) as a substrate.

M Narita1, E Nagai, H Hagiwara, M Aburada, T Yokoi, T Kamataki.   

Abstract

1. 7-Ethyl-10-[4-(piperidino)-1-piperidino] carbonyloxycamptothecin (CPT-11), a potent anticancer agent currently under development for clinical use, is metabolized in vivo to 7-ethyl-10-hydroxycamptothecin (SN-38), which is subsequently conjugated to 7-ethyl-10-hydroxycamptothecin glucuronide (SN-38-glucuronide). The SN-38-glucuronide was hydrolysed by beta-glucuronidase from E. coli to aglycones and glucuronic acid. 2. Four purified natural glucuronides including baicalin, wogonoside, luteolin-3'-glucuronide, and glycyrrhizin, inhibited beta-glucuronidase using SN-38-glucuronide as substrate. The inhibition potencies of these natural glucuronides toward beta-glucuronidase were similar to that of saccharic acid 1,4-lactone. 3. These results indicate that plant materials of Kampo (Japanese herbal) medicines containing these glucuronides could be used in vivo to decrease the enterohepatic circulation of SN-38 and possibly that of other drugs.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8484262     DOI: 10.3109/00498259309059356

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  15 in total

Review 1.  The role of beta-glucuronidase in drug disposition and drug targeting in humans.

Authors:  B Sperker; J T Backman; H K Kroemer
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

2.  Excretion into gastrointestinal tract of irinotecan lactone and carboxylate forms and their pharmacodynamics in rodents.

Authors:  K Arimori; N Kuroki; A Kumamoto; N Tanoue; M Nakano; E Kumazawa; A Tohgo; M Kikuchi
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

Review 3.  Herb-drug interactions: a literature review.

Authors:  Zeping Hu; Xiaoxia Yang; Paul Chi Lui Ho; Sui Yung Chan; Paul Wan Sia Heng; Eli Chan; Wei Duan; Hwee Ling Koh; Shufeng Zhou
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 4.  Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis.

Authors:  Umang Swami; Sanjay Goel; Sridhar Mani
Journal:  Curr Drug Targets       Date:  2013-06       Impact factor: 3.465

5.  Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats.

Authors:  Kazuhiko Arimori; Noriaki Kuroki; Muneaki Hidaka; Tomomi Iwakiri; Keishi Yamsaki; Manabu Okumura; Hiroshige Ono; Norito Takamura; Masahiko Kikuchi; Masahiro Nakano
Journal:  Pharm Res       Date:  2003-06       Impact factor: 4.200

6.  Saccharic acid 1.4-lactone protects against CPT-11-induced mucosa damage in rats.

Authors:  Marina Fittkau; Wieland Voigt; Hans-Jürgen Holzhausen; Hans-Joachim Schmoll
Journal:  J Cancer Res Clin Oncol       Date:  2004-07       Impact factor: 4.553

Review 7.  Current perspectives on camptothecins in cancer treatment.

Authors:  J Dancey; E A Eisenhauer
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

8.  Fish oil supplementation enhanced CPT-11 (irinotecan) efficacy against MCF7 breast carcinoma xenografts and ameliorated intestinal side-effects.

Authors:  W E Hardman; M P Moyer; I L Cameron
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

9.  Herbal medicines for the treatment of cancer chemotherapy-induced side effects.

Authors:  Shunsuke Ohnishi; Hiroshi Takeda
Journal:  Front Pharmacol       Date:  2015-02-10       Impact factor: 5.810

Review 10.  Three measurable and modifiable enteric microbial biotransformations relevant to cancer prevention and treatment.

Authors:  Gregory A Plotnikoff
Journal:  Glob Adv Health Med       Date:  2014-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.